Skip to main content

Main Line's Aclipse Therapeutics lands $720K from Australia research firm to advance ALS therapy

The grant was awarded by Australia's largest independent backer of amyotrophic lateral sclerosis research.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.